Accession Number : ADA613437


Title :   EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer


Descriptive Note : Annual rept. 15 Aug 2013-14 Aug 2014


Corporate Author : STANFORD UNIV CA


Personal Author(s) : Loo, Jr, Billy W


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a613437.pdf


Report Date : Sep 2014


Pagination or Media Count : 9


Abstract : Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, 18F-EF5, is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting. Our objectives are (1) to understand the prevalence of hypoxia detectable by imaging in early stage NSCLC; (2) to validate 18F-EF5 PET as an indicator of tumor oxygenation status in this patient population; and (3) to evaluate 18F-EF5 PET as a prognostic imaging biomarker for local primary tumor control after SABR.


Descriptors :   *HYPOXIA , *LUNG CANCER , *NEOPLASMS , *RADIOTHERAPY , ABLATION , AGING(MATERIALS) , CANCER , CANCER SCREENING , CLINICAL MEDICINE , CONTROL , IMAGES , INDICATORS , LUNG , MEASUREMENT , OXYGEN , PATIENTS , POPULATION , RESISTANCE , RESPONSE , SURGERY , VALIDATION


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE